You are here:

Sildenafil citrate 20mg tablets (Revatio®)


Following a full submission.

Sildenafil citrate (Revatio) is accepted for restricted use within NHS Scotland for the treatment of patients with pulmonary arterial hypertension classified as WHO functional class III, to improve exercise capacity.

This is an orphan indication for sildenafil with limited clinical evidence from short-term clinical trials. It is restricted to initiation by specialists working in the Scottish Pulmonary Vascular Unit and by physicians experienced in the management of pulmonary vascular disease.

Drug Details

Drug Name: Sildenafil citrate 20mg tablets (Revatio®)
SMC Drug ID: 235/06
Manufacturer: Pfizer Ltd
Indication: Pulmonary arterial hypertension
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 February 2006